Monopar jumps after doctor letter in Journal of Hepatology

Monopar Therapeutics (MNPR) earlier today announced that the Journal of Hepatology published a peer-reviewed letter to the editor, authored by Wilson disease physicians, entitled “Oral Bis-choline Tetrathiomolybdate Rapidly Improves Copper Balance in Patients with Wilson Disease.” In the letter, the authors explain that the earlier conclusion from the Phase 2 ALXN1840-WD-204 study – that ALXN1840 did not promote copper excretion – was based on a methodological limitation in the copper balance equation, which only accounted for certain routes of copper loss, the company noted. By controlling for the other routes of copper loss by comparing pre- and post-ALXN1840 treatment, the analysis demonstrates that ALXN1840 statistically significantly improved copper balance over the duration of the study, according to Monopar. Shares of Monopar are up 6% to $4.14 to $71.82 in morning trading.